CytoSorbents Corp. on Monday announced the promotion of chief operating officer Vincent J. Capponi to president and chief operating officer, effective immediately.
“I am very pleased to announce the promotion of Vince to president and chief operating officer of CytoSorbents,” Dr. Phillip Chan, CEO of CytoSorbents, said. “Having worked closely with Vince for over a dozen years, much of the success of CytoSorbents to date is a testament to his many outstanding contributions in all aspects of the company. In his 18 years with CytoSorbents, he has helped to manage the daily operations of the company, with a focus on manufacturing, engineering, regulatory, clinical studies, new product development and research.”
The Monmouth Junction-based critical care immunotherapy company said most recently, Capponi was instrument in executing the regulatory strategy that led to the FDA emergency use authorization of CytoSorb for adult, critically-ill COVID-19 patients.
“This has … enabled us to rapidly respond to the increased need for CytoSorb around the globe during this COVID-19 pandemic, including here in the U.S. under the EUA,” Chan said.
As president and COO, Capponi will continue to oversee the company’s operations and start focusing on developing new opportunities for CytoSorb and other technologies.
“At CytoSorbents, I have experienced what I believe is a once-in-a-lifetime opportunity: to work with a new product concept and be part of a fantastic team to transform that idea into a life-saving therapy worldwide. We are just beginning to see the true potential of CytoSorb and what it could mean for the future of critical care and cardiac surgery. As president and COO, I am honored to have been given this opportunity and look forward to continuing to work with Phil and the management team, to take on new challenges, help make our corporate goals a reality, increase the overall value of our company, and most importantly, save lives,” Capponi said.